


NOTARY CERTIFICATION

I, **Theresa Papale Munro**, a duly commissioned Notary Public for the Commonwealth of Pennsylvania, certify that the attached is a true and correct copy of the duly executed priority assignment from the inventors to **GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No. 4) LIMITED**.



Notary Public

My Commission Expires: April 29, 2029

Dated: 21 May 2025

Commonwealth of Pennsylvania - Notary Seal
Theresa Papale Munro, Notary Public
Montgomery County
My commission expires April 29, 2029
Commission number 1249252
Member, Pennsylvania Association of Notaries



ASSIGNMENT

WHEREAS I/WE, **Janos BOTYANSZKI, Kevin DUFFY** both of Collegeville, United States of America, and **Yong Eun CHOI** of Cambridge, United States of America, all citizens of United States of America (hereinafter called "the inventor(s)") have invented or discovered certain improvements in **THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS AND USES THEREOF** (hereinafter referred to as "the invention and improvements") for which provisional applications under 35 U.S.C. §111(b) were filed in the United States of America on 09 Dec 2022 under application number 63/386709 and on 26 July 2023 under application number 63/515641 respectively.

WHEREAS, GLAXOSMITHKLINE LLC, a company incorporated in the State of Delaware, USA, whose registered address is 251 Little Falls Drive, Wilmington, Delaware 19808, United States of America, is desirous of acquiring the whole right, title and interest in and to said invention and improvements, and in and to any applications for said invention and improvements, including the right to claim priority, and in and to any Letters Patent to be obtained therefor, in all countries, including the United States, its territories and possessions, and

WHEREAS GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED, a company incorporated in England whose registered address is 980 Great West Road, Brentford, Middlesex TW8 9GS, England, is desirous of acquiring from GLAXOSMITHKLINE LLC the whole right, title and interest in and to the invention and improvements and in and to the application, and

WHEREAS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED a company incorporated in England whose registered address is GSK Medicines Research Centre, Gunnels Wood Road, Stevenage, SG1 2NY, United Kingdom, (formerly of 980 Great West Road, Brentford, Middlesex TW8 9GS, England) is desirous of acquiring the whole right, title and interest in and to the invention and improvements and in and to any applications for the invention and improvements and any Letters Patent to be obtained therefor, in all countries, including the United States of America, its territories and possessions;

NOW, THEREFORE, to all whom it may concern, be it known that I/we, **Janos BOTYANSZKI, Yong Eun CHOI, Kevin DUFFY**, for good and valuable consideration unto me/us moving, the receipt whereof is hereby acknowledged, have sold, assigned and transferred, and by these presents do sell, assign and transfer my/our whole right, title and interest in and to said invention and improvements to said GLAXOSMITHKLINE LLC, throughout the United States of America, its territories and possessions, and in and to said application, and any extensions, reissues, continuations, continuations-in-part, and any divisions

thereof, and in and to any and all Letters Patent of the United States of America, including any priority rights under the International Convention

AND, my/our whole right, title and interest in and to said invention and improvements to GLAXOSMITHKLINE LLC, in all other countries throughout the world, and in and to any applications in said other countries, and continuations-in-part, patents of addition, revalidation patents, patents of importation, registrations, and any renewals, extensions and divisions thereof, and in and to any and all Letters Patent of said all other countries which may be granted on said invention and improvements including any priority rights under the International Convention.

GLAXOSMITHKLINE LLC in turn hereby assigns and transfers to GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED its whole right, title and interest in all countries, including the United States of America, its territories and possessions in and to the invention and improvements and in and to the application including the right to claim priority from the application in respect of any subsequent applications, and in and to any divisional application, continuation or continuation in part application thereof, and in and to any Supplementary Protection Certificate, extension or re-issue thereof, and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED in turn hereby assigns and transfers to GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED its whole right, title and interest in all countries, including the United States of America, its territories and possessions in and to the invention and improvements and in and to the application including the right to claim priority from the application in respect of any subsequent applications, and in and to any divisional application, continuation or continuation in part application thereof, and in and to any Supplementary Protection Certificate, extension or re-issue thereof

AND I/we the inventor(s) and GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED hereby authorise and request any patent arising therefrom, in all countries, including the United States of America, its territories and possessions, be issued to GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED;

AND GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED hereby, and I/we the inventor(s) for myself/ourselves and my/our respective executors and legal representatives hereby, agree at the request and cost of GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED to provide information and make execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED, its successors and assigns, the whole right, title and interest in and to the invention and

70262US01P/70262US02P

improvements and in and to the application hereby assigned and transferred in all countries, including the United States of America, its territories and possessions.


IN WITNESS whereof and with effect from the 9 December 2022, the inventor(s) and the Attorney & Authorised Official of GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED and GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED have hereunto set their respective hands.

Inventor Name

Signature

Date

Janos BOTYANSZKI: _____



11/08/2023

Yong Eun CHOI: _____

Kevin DUFFY: _____

SIGNED by _____ As the Attorney &
Authorised Official of GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE RESEARCH AND
DEVELOPMENT LIMITED and GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED:

Signature

Date: _____

improvements and in and to the application hereby assigned and transferred in all countries, including the United States of America, its territories and possessions.

IN WITNESS whereof and with effect from the 9 December 2022, the inventor(s) and the Attorney & Authorised Official of GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED and GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED have hereunto set their respective hands.


Inventor Name

Signature

Date

Janos BOTYANSZKI: _____

Young
Yong Eun CHOI:
YC

 11 / 8 / 2023

Kevin DUFFY: _____

SIGNED by _____ As the Attorney &
Authorised Official of GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE RESEARCH AND
DEVELOPMENT LIMITED and GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED:

Signature

Date: _____

improvements and in and to the application hereby assigned and transferred in all countries, including the United States of America, its territories and possessions.

IN WITNESS whereof and with effect from the 9 December 2022, the inventor(s) and the Attorney & Authorised Official of GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED and GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED have hereunto set their respective hands.

Inventor Name

Signature

Date

Janos BOTYANSZKI: _____

Yong Eun CHOI: _____

Kevin DUFFY: _____



November 8 2023

SIGNED by _____ As the Attorney & Authorised Official of GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED and GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED:

Signature

Date: _____

70262US01P/70262US02P

improvements and in and to the application hereby assigned and transferred in all countries, including the United States of America, its territories and possessions.

IN WITNESS whereof and with effect from the 9 December 2022, the inventor(s) and the Attorney & Authorised Official of GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED and GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED have hereunto set their respective hands.

Inventor Name

Signature

Date

Janos BOTYANSZKI: _____

Yong Eun CHOI: _____

Kevin DUFFY: _____


SIGNED by RACHEL M. THORNLEY As the Attorney & Authorised Official of GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED and GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED:


Signature

Date: 5 December 2023

NOTARY CERTIFICATION

I, **Theresa Papale Munro**, a duly commissioned Notary Public for the Commonwealth of Pennsylvania, certify that the attached is a true and correct copy of the duly executed priority assignment from the inventors to **IDEAYA Biosciences, Inc.**



Notary Public

My Commission Expires: April 29, 2029

Dated: 21 May 2025

Commonwealth of Pennsylvania - Notary Seal
Theresa Papale Munro, Notary Public
Montgomery County
My commission expires April 29, 2029
Commission number 1249252
Member, Pennsylvania Association of Notaries



ASSIGNMENT

WHEREAS, I/We, **Claire L. Neilan**, a citizen of Great Britain, and **Marcus Michael Fischer**, a citizen of United States of America (“**the inventors**”), have invented a certain new and useful invention or discovered certain improvements in **THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS AND USES THEREOF** (hereinafter referred to as “the invention and improvements”), for which provisional applications under § 111(b) were filed in the United States of America on **09 December 2022** under application number **63/386,709** and on **26 July 2023** under application number **63/515,641**; and for which a PCT international application will be filed. I/We, **the inventors**, hereby authorize **IDEAYA Biosciences, Inc.**, and request that the filing date and the application number of said PCT application, when known, be inserted in the parentheses below.

(PCT/ EP2023/084669 filed 07 Dec 2023)

WHEREAS, **IDEAYA Biosciences, Inc.**, having its principal place of business at 7000 Shoreline Court, Suite # 350, South San Francisco, CA 94080, is desirous of acquiring all rights, title and interest in and to said invention and improvements, in and to said applications for said invention and improvements, including without limitation the right to claim priority, and in and to any and all Patents that may be granted for or upon said invention and improvements and applications in the United States of America, its territories and possessions, and anywhere in the world.

NOW THEREFORE, to all whom it may concern, be it known that for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, I/We, **the inventors**, have sold, assigned and transferred, and by these presents do sell, assign and transfer unto the said **IDEAYA Biosciences, Inc.**, the full and exclusive right, title and interest, throughout the world, in, to and

under the following:

- (a) the invention and improvements as set forth and described, for example, in the patent application specifications identified above;
- (b) all patent applications identified above;
- (c) any and all patent applications, including Patent Cooperation Treaty (PCT) applications, directed to the invention and improvements as set forth and described, for example, in the patent application specifications identified above;
- (d) any and all refilings, divisions, continuations, and continuations-in-part of the patent applications identified above;
- (e) any and all patents of the United States of America which may issue from any of the above items;
- (f) any and all extensions, reissue, and reexamination certificates of those patents of the United States of America which may issue from any of the above items;
- (g) any and all applications for the invention and improvements filed in any and all countries foreign to the United States of America;
- (h) any and all refilings, divisions, and continuations of those foreign-filed applications;
- (i) any and all patents, certificates including without limitation Supplementary Protection Certificate, and registrations of countries foreign to the United States of America which may issue from those foreign-filed applications, refilings, divisions, and continuations;
- (j) any and all renewals and extensions of, and additions to, the foreign-filed applications and patents, certificates including without limitation Supplementary Protection Certificate, and

- registrations related thereto;
- (k) the right to claim priority to any of the foregoing, including without limitation priority rights under the International Convention; and
 - (l) any and all claims, causes of action, and damages for past, present, and future infringement or other unauthorized use of the above items including without limitation provisional rights to reasonable royalties pursuant to 35 U.S.C. § 154(d), along with the right to sue and to collect damages and other relief from any and all parties.

I/We, **the inventors**, further agree that I/We will promptly execute and deliver to **IDEAYA Biosciences, Inc.** or its legal representatives any and all papers, instruments, and affidavits, including without limitation applications, declarations, oaths, and petitions, required to apply for, obtain, maintain, issue, and enforce all of the items listed above.

All of the above shall be held and enjoyed by **IDEAYA Biosciences, Inc.** and its successors, legal representatives, and assigns for their own use and benefit, for the full term for which the protections listed above may be granted, and **the inventors** authorize and request the United States Patent and Trademark Office and the patent office of all foreign countries to issue any Patents granted for said invention and improvements, whether on an application for said invention and improvements set forth above, or on any subsequently filed provisional, non-provisional, divisional, continuation, continuation-in-part, reissue, or other related application, to **IDEAYA Biosciences, Inc.**, its successors and assigns, as the assignee of their entire interest in said invention and improvements and applications.

ASSIGNOR:

Claire L. Neilan

CNeil

Signature

03 NOVEMBER 2023

Date

Signed in my presence and acknowledged to be an assignment of the application herein
above referred to:

WITNESS

ST. HELENA, CALIFORNIA

Signed At (City/State)

JORDAN FRIDMAN

Name

[Signature]

Signature

03 NOVEMBER 2023

Date

ASSIGNOR:

Marcus M. Fischer

Marcus M. Fischer 11/3/23
Signature Date

Signed in my presence and acknowledged to be an assignment of the application herein
above referred to:

WITNESS

Santa Clara, CA
Signed At (City/State)

Sandra Fischer
Name

Sandra Fischer
Signature

11/3/23
Date

ASSIGNEE:

IDEAYA Biosciences, Inc.

Jason S Throne
Signature

November 3, 2023
Date

NAME: Jason S Throne

TITLE: Chief Legal Officer

Representative Duly Authorized by IDEAYA Biosciences, Inc.

Signed in my presence and acknowledged to be an assignment of the application herein
above referred to:

WITNESS

OAKLAND, CA
Signed At (City/State)

AILEEN THORNE
Name

Jason Throne
Signature

11/3/23
Date

From the INTERNATIONAL BUREAU

PCTNOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

GLADWIN, Amanda
GSK
980 Great West Road
Brentford Middlesex TW8 9GS
ROYAUME-UNIDate of mailing (day/month/year)
26 May 2025 (26.05.2025)Applicant's or agent's file reference
70262WO01International application No.
PCT/EP2023/084669**IMPORTANT NOTIFICATION**International filing date (day/month/year)
07 December 2023 (07.12.2023)

1. The following indications appeared on record concerning:

☒ the applicant ☐ the inventor ☐ the agent ☐ the common representative

Name and Address

IDEAYA BIOSCIENCES, INC.
7000 Shoreline Court, Suite 350
South San Francisco, California 94080
UNITED STATES OF AMERICA

State of Nationality

US

State of Residence

US

Telephone No.

Facsimile No.

E-mail address

cipukadmin@gsk.com

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☐ the person ☐ the name ☒ the address ☐ the nationality ☐ the residence

Name and Address

IDEAYA BIOSCIENCES, INC.
5000 Shoreline Court, Suite 300
South San Francisco, California 94080
UNITED STATES OF AMERICA

State of Nationality

US

State of Residence

US

Telephone No.

Facsimile No.

E-mail address

cipukadmin@gsk.com

☒ Notifications by e-mail

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

☒ the receiving Office
☒ the International Searching Authority
☐ the Authority(ies) specified for supplementary search☐ the International Preliminary Examining Authority
☒ the designated Offices concerned
☐ the elected Offices concerned
☐ other:The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

Nissen Diana

e-mail pct.team6@wipo.int

Telephone No. +41 22 338 74 06

From the INTERNATIONAL BUREAU

PCTNOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

GLADWIN, Amanda
GSK
980 Great West Road
Brentford Middlesex TW8 9GS
ROYAUME-UNIDate of mailing (day/month/year)
26 May 2025 (26.05.2025)Applicant's or agent's file reference
70262WO01International application No.
PCT/EP2023/084669**IMPORTANT NOTIFICATION**International filing date (day/month/year)
07 December 2023 (07.12.2023)

1. The following indications appeared on record concerning:

☐ the applicant ☒ the inventor ☐ the agent ☐ the common representative

Name and Address

FISCHER, Marcus Michael
IDEAYA BIOSCIENCES, INC.
7000 Shoreline Court, Suite 350
South San Francisco, California 94080
UNITED STATES OF AMERICA

State of Nationality

State of Residence

Telephone No.

Facsimile No.

E-mail address

cipukadmin@gsk.com

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☐ the person ☐ the name ☒ the address ☐ the nationality ☐ the residence

Name and Address

FISCHER, Marcus Michael
IDEAYA BIOSCIENCES, INC.
5000 Shoreline Court, Suite 300
South San Francisco, California 94080
UNITED STATES OF AMERICA

State of Nationality

State of Residence

Telephone No.

Facsimile No.

E-mail address

cipukadmin@gsk.com

☒ Notifications by e-mail

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

☒ the receiving Office
☒ the International Searching Authority
☐ the Authority(ies) specified for supplementary search☐ the International Preliminary Examining Authority
☒ the designated Offices concerned
☐ the elected Offices concerned
☐ other:The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

Nissen Diana

e-mail pct.team6@wipo.int

Telephone No. +41 22 338 74 06

From the INTERNATIONAL BUREAU

PCTNOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

GLADWIN, Amanda
GSK
980 Great West Road
Brentford Middlesex TW8 9GS
ROYAUME-UNIDate of mailing (day/month/year)
26 May 2025 (26.05.2025)Applicant's or agent's file reference
70262WO01**IMPORTANT NOTIFICATION**International application No.
PCT/EP2023/084669International filing date (day/month/year)
07 December 2023 (07.12.2023)

1. The following indications appeared on record concerning:

☐ the applicant ☒ the inventor ☐ the agent ☐ the common representative

Name and Address

NEILAN, Claire L.
IDEAYA BIOSCIENCES, INC.
7000 Shoreline Court, Suite 350
South San Francisco, California 94080
UNITED STATES OF AMERICA

State of Nationality

State of Residence

Telephone No.

Facsimile No.

E-mail address

cipukadmin@gsk.com

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☐ the person ☐ the name ☒ the address ☐ the nationality ☐ the residence

Name and Address

NEILAN, Claire L.
IDEAYA BIOSCIENCES, INC.
5000 Shoreline Court, Suite 300
South San Francisco, California 94080
UNITED STATES OF AMERICA

State of Nationality

State of Residence

Telephone No.

Facsimile No.

E-mail address

cipukadmin@gsk.com

☒ Notifications by e-mail

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

☒ the receiving Office
☒ the International Searching Authority
☐ the Authority(ies) specified for supplementary search☐ the International Preliminary Examining Authority
☒ the designated Offices concerned
☐ the elected Offices concerned
☐ other:The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

Nissen Diana

e-mail pct.team6@wipo.int

Telephone No. +41 22 338 74 06

NATIONAL STAGE DATA SHEET

Application No. PCT/EP2023/084669

Application Date 07 Dec 2023

CASE NO:

70262

APPLICANT(S):

GlaxoSmithKline Intellectual Property (No.4) Limited

GSK Medicines Research Centre

Gunnels Wood Road

Stevenage SG1 2NY

United Kingdom

IDEAYA Biosciences, Inc.

5000 Shoreline Court, Suite 300

South San Francisco California 94080

United States of America

*(Request to correct address was sent 23 May 2025; IB306 will be sent upon receipt)

ADDRESS:

Please send all correspondence related to this matter to US_CIPKOP@GSK.com. Please do not send facsimiles or correspondence via airmail.

Please do not send us confirmation copies of any correspondence. Only original documents eg. Letters Patent should be sent by mail.

TITLE:

THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE
THETA INHIBITORS AND USES THEREOF

TOTAL NUMBER OF
WORDS IN SPEC:

16,199

PRIORITY:

U.S. App No. 63/386709 filed 09 Dec 2022

U.S. App No. 63/515641 filed 26 Jul 2023

INVENTOR(S):

Janos BOTYANSZKI

c/o 1250 South Collegeville Road

Collegeville, Pennsylvania 19426

United States of America

Nationality: US

Kevin DUFFY

c/o 1250 South Collegeville Road
Collegeville, Pennsylvania 19426
United States of America
Nationality: US

Claire L. NEILAN

c/o 5000 Shoreline Court, Suite 300
South San Francisco, California 94080
United States of America
Nationality: GB

Marcus Michael FISCHER

c/o 5000 Shoreline Court, Suite 300
South San Francisco, California 94080
United States of America
Nationality: US

Young Eun CHOI

c/o 200 Cambridge Park Drive, 6th Floor
Cambridge, Massachusetts 02140
United States of America
Nationality: US

DERIVATION OF RIGHTS:

Assignment